Novel Single Inhibitor of HDAC6/8 and Dual Inhibitor of PI3K/HDAC6 as Potential Alternative Treatments for Prostate Cancer

Background: Prostate cancer is the second most frequently diagnosed malignancy worldwide. Here, the cytotoxic and antimetastatic effects of a new HDAC6/8 inhibitor, LASSBio-1911, and a new dual-PI3K/HDAC6 inhibitor, LASSBio-2208, were evaluated against PC3 prostate cancer cell line. Methods: A MTT a...

Descripción completa

Detalles Bibliográficos
Autores principales: Guerra, Fabiana Sélos, Rodrigues, Daniel Alencar, Fraga, Carlos Alberto Manssour, Fernandes, Patricia Dias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143108/
https://www.ncbi.nlm.nih.gov/pubmed/33919077
http://dx.doi.org/10.3390/ph14050387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143108/
https://www.ncbi.nlm.nih.gov/pubmed/33919077
http://dx.doi.org/10.3390/ph14050387

Ejemplares similares